Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells

Cancer Research

Volumn 57, Issue 13, 1997, Pages 2559-2563

  Rodriguez, Ron ^a   Schuur, Eric R ^b   Lim, Ho Yeong ^a   Henderson, Gail A ^b   Simons, Jonathan W ^a   Henderson, Daniel R ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Calydon Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; VIRUS VECTOR;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GENE TRANSFER; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; VIRUS ATTENUATION; VIRUS GENE;

ADENOVIRUS E1A PROTEINS; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030790684     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Aumüller, G., Seitz, J., Lilja, H., Abrahamsson, P-A., von der Kammer, H., and Scheit, K-H. Species-and Organ-specificity of secretory proteins derived from human prostate and seminal vesicles. Prostate, 17: 31-40, 1990.
2. Wingo, P. A., Troy, T., and Bolden, S. Cancer statistics, 1996. CA Cancer J. Clin., 46: 113-125, 1996.
3. Yu, H., Giai, M., Diamandis, E. P., Katsaros, D., Sutherland, D. J. A., Levesque, M. A., Roagna, R., Ponzone, R., and Sismondi, P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res., 55: 2104-2110, 1995.
4. Catalona, W. J. Management of cancer of the prostate. N. Engl. J. Med., 331: 996-1004, 1994.
5. Hsieh, W. S., and Simons, J. W. Systemic therapy of prostate cancer. New concepts from prostate cancer tumor biology. Cancer Treat. Rev., 19: 229-260, 1993.
6. Schuur, E. R., Henderson, G. A., Kmetec, L. A., Miller, J. D., Lamparski, H. G., and Henderson, D. R. Prostate-specific antigen expression is regulated by an upstream enhancer. J. Biol. Chem., 271: 7043-7051, 1996.
7. Scher, H. I., and Fossa, S. Prostate cancer in the era of prostate-specific antigen. Curr. Opin. Oncol., 7: 281-291, 1995.
8. Wilding, G. Endocrine control of prostate cancer. Cancer Surv., 23: 43-62, 1995.
9. Smith, P. H. Hormone therapy: an overview. Cancer Surv., 23: 171-181, 1995.
10. Walsh, P. C. Radical prostatectomy: a procedure in evolution. Semin. Oncol., 21: 662-671, 1994.
11. Berns, K. I., and Giraud, C. Adenovirus and adeno-associated virus as vectors for gene therapy. Ann. N.Y. Acad. Sci., 772: 95-104, 1995.
12. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant the replicates selectively in p53-deficient human tumor cells. Science (Washington DC), 274: 373-376, 1996.
13. Wilson, J. M. Adenoviruses as gene-delivery vehicles. N. Engl. J. Med., 334: 1185-1187, 1996.
14. Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A., and Murphy, G. P. LNCaP model of human prostatic carcinoma. Cancer Res., 43: 1809-1818, 1983.
15. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkman, A. O., and Mulder, E. A. Mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-andogens. Biochem. Biophys. Res. Commun., 173: 534-540, 1990.
16. Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol., 36: 59-72, 1977.
17. McKinnon, R. D., Bacchetti, S., and Graham, F. L. Tn 5 mutagenesis of the transforming genes of human adenovirus type 5. Gene, 19: 33-42, 1982.
18. Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA, 91: 8802-8806, 1994.
19. McGrory, W. J., Bautista, D. S., and Graham, F. L. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology, 163: 614-617, 1988.
20. Graham, F, L., and Van Der Eb, A. J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology, 52: 456-467, 1973.
21. Lim, D. J., Liu, X-1., Sutkowski, D. M., Braun, E. J., Lee, C., and Kozlowski, J. M. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate, 22: 109-118, 1993.
22. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
23. Gleave, M. E., Hsieh, J-T., Wu, H. C., von Eshenbach, A. C., and Chung, L. W. K. Serum prostate-specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res., 52: 1598-1605, 1992.
24. Grodzicker, T., Lewis, J. B., and Anderson, C. W. Conditional lethal mutants of adenovirus type 2-simian virus 40 hybrids. II. Ad2+ND1 host-range mutants that synthesize fragments of the the Ad2+ND1 3OK protein. J. Virol., 19: 559-571, 1976.
25. Breiding, D. E., Edbauer, C. A., Tong, J. Y., Byrd, P., Grand, R. J. A., Gallimore, P. H., and Williams, J. Isolation and characterization of adenovirus type 12 E1 host-range mutants defective for growth in nontransformed human cells. Virology, 164: 390-402, 1988.
26. Hitt, M. M., and Graham, F. L. Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. Virology, 179: 667-678, 1990.
27. Telling, G. C., Perera, S., Szatkowski-Ozers, M., and Williams, J. Absence of an essential regulatory influence of the adenovirus E1B 19-kilodalton protein on viral growth and early gene expression in human diploid WI38, HeLa, and A549 cells. J. Virol., 68: 541-547, 1994.
28. Hui, M. B. V., Lien, E. J., and Trousdale, M. D. Inhibition of human adenoviruses by 1-(2′-hydroxy-5′-methoxybenzylidene)amino-3-hydroxyguanidine tosylate. Antiviral Res., 24: 261-273, 1994.
29. Jones, N., and Shenk, T. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc. Natl. Acad. Sci. USA, 76: 3665-3669, 1979.
30. Mineta, T., Rabkin, S. D., Tazaki, T., Hunter, W. D., and Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1: 938-943, 1995.
31. Elliott, W. L., Roberts, B. J., Howard, C. T., and Leopold, W. R. I. Chemotherapy with [SP-4-3-(R)]-[1, 1-cyclobutanedicarboxylato(2)](2-methyl-1,4-butanediamine-N,N′)platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Cancer Res., 54: 4412-4418, 1994.
32. Ghazizadeh, M., Kagawa, S., Maebayashi, K., Izumi, K., and Kurokawa, K. Prostatic origin of metastases: immunoperoxidase localization of prostate-specific antigen. Ural. Int., 39: 9-12, 1984.
33. Andriole, G. L., and Catalona, W. J., M. D. The diagnosis and treatment of prostate cancer. Annu. Rev. Med., 42: 9-15, 1991.
34. Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. L., and Walsh, P. C. The use of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J. Urol., 150: 110-114, 1993.
35. Worgall, S., Wolff, G., Falck-Pendersen, E., and Crystal, R. G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther., 8: 37-44, 1997.
36. Yang, Y., Li, Q., Ertl, J., and Wilson, J. M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA, 91: 4407-4411, 1994.
37. Mack, C. A., Song, W-R., Carpenter, H., Wickham, T. J., Kovesdi, I., Harvey, B-G., Magovern, C. J., Isom, O. W., Rosengart, T., Falck-Pederson, E., Hackett, N. R., Crystal, R. G., and Mastrangeli, A. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of on alternate serotype. Human Gene Ther., 8: 99-109, 1997.
38. Vilquin, J-T., Guérette, B., Kinoshita, I., Roy, B., Goulet, M., Gravel, C., Roy, R., and Tremblay, J. P. FK506 Immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum. Gene Ther., 6: 1391-1401, 1995.
39. Engelhardt, J. F., Ye, X., Doranz, B., and Wilson, J. M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA, 91: 6196-6200, 1994.
40. Yang, Y., Xiang, Z., Ertl, H. C. J., and Wilson, J. M. Upregulation of class I major histocompatibility complex antigens by interferon γ is necessary for T cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc. Natl. Acad. Sci. USA, 92: 7257-7261, 1995.
41. Dahiya, R., Deng, G., Chen, K. M., Chui, R. M., Haughney, P. C., and Narayan, P. p53 tumor-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic cancer. Br. J. Cancer, 74: 264-268, 1996.
42. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I., and Isaacs, W. B. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res., 56: 3814-3822, 1996.
43. Deguchi, T., Doi, T., Ehara, H., Ito, S-i., Takahashi, Y., Nishino, Y., Fujihiro, S., Kawamura, T., Komeda, H., Horie, M., Kaji, H., Shimokawa, K., Tanaka, T., and Kawada, Y. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res., 53: 5350-5354, 1993.
44. Smith, R. R., Huebner, R. J., Rowe, W. P., Schatten, W. E., and Thomas, L. B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer (Phila.), 9: 1211-1218, 1956.